Renalytix plc

("Renalytix" or the "Company")

Publication of Annual Report 2025

&

 Notice of 2025 Annual General Meeting

LONDON and NEW YORK, 4 November 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, with kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in chronic kidney disease, announces that the Annual Report for the year ended 30 June 2025 and the Notice of 2025 Annual General Meeting ("AGM") have now been published on the Company's website and will be posted to shareholders who have not consented to receive electronic communications tomorrow morning.

The Annual report is available on the Company website here: https://investors.renalytix.com/annual-half-year-reports/

The full Notice of AGM can be found here: https://investors.renalytix.com/documents/

The AGM will be held in-person on 9 December 2025 at 10.00 (GMT) at 6 Stratton Street Mayfair, London W1J 8LD. 

Any shareholder wishing to attend is required to register by contacting Walbrook PR via email at renalytix@walbrookpr.com or by telephone at +44 (0)20 7933 8780.

For further information, please contact:

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.

The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).

KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix. For information about the kidneyintelX,dkd test, visit kidneyintelx.com.